¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022) : 2022-11-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022) : 2022-11-19
±³À°ÀÏÀÚ : 2022-11-19
±³À°Àå¼Ò : ¼ÛµµÄÁº¥½Ã¾Æ  
±³À°ÁÖÁ¦ : ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022)
ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Çö°æ¸²
¿¬¶ôó : 032-460-3663  
À̸ÞÀÏ : kphs.or@gmail.com      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ÀÎõ±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 10,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:00~09:15 Pulmonary hypertension classification case: CTD-PAH(Group 1)  ¹éÀç¼÷(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:15~09:30 Pulmonary hypertension classification case: LHD-PH: IpcPH, CpcPH, and LVAD-PH(Group 2)  À念¿ì(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:30~09:45 Pulmonary hypertension classification case: ILD-PH(Group 3)  ÀåÇ×Á¦(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:45~10:00 Pulmonary hypertension classification case:CTEPH(Group 4)  ¾Èö¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:00~10:15 Pulmonary hypertension classification case:Misc. Multifactorial-PH(Group 5)  ÀÌÁÖÈñ(ÃæºÏÀÇ´ë) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:15~10:35 Pulmonary hypertension classification case based learning  ±è´ëÈñ(¿ï»êÀÇ´ë) 
È޽Ġ11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:35~10:55 È޽Ġ () 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:55~11:25 ESC-ERS 2022 Guideline  Stephan Rosencranz(University of Cologne, Germany) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 11:25~11:40 Lessons 2020 Korean PH guideline  ¹ÚÀçÇü(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 11:40~11:55 Proposals for next Korean PH guideline  ÃÖÁ¤Çö(ºÎ»êÀÇ´ë) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 11:55~12:10 How to make New Korean PH Guideline?  ³ªÁø¿À(°í·ÁÀÇ´ë) 
½Ä»ç 11-19 ÇÁ¸®¹Ì¾îº¼·ë 12:10~13:10 ½Ä»ç  () 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:10~13:25 Update of PH incidence in Korea  ÀüÂùÈ«(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:25~13:40 Update of insurance system for PH drugs in Korea  Çϱâ¼ö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:40~13:55 How to use new drug and devices for PH in Korea  ±è±â¹ü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:55~14:10 Government support for PH treatment in Japan  Hiromi Matsubara(Okayama University Graduate School of Medicine, Japan) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:10~14:25 Policy session for pulmonary hypertension treatment  ±è°èÈÆ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:25~14:40 South Korea_Muldisciplinary Approach for Better Outcome  ¾È°æÁø(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:40~14:55 Japan_Muldisciplinary Approach for Better Outcome  Yu Taniguchi(Kobe University) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:55~15:10 China_Muldisciplinary Approach for Better Outcome  Yu-Ping Zhou(Peking Union Medical College Hospital) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 15:10~15:25 Taiwan (Genetic study for pulmonary arterial hypertension-central Taiwan study)  Kae-woei Liang(China Medical University Hospital, Taiwan) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 15:25~15:40 EASOPH session: Muldisciplinary Approach for Better Outcome  Á¤ÁßÈ­(Á¶¼±ÀÇ´ë) 
È޽Ġ11-19 ÇÁ¸®¹Ì¾îº¼·ë 15:40~16:00 È޽Ġ () 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:00~16:15 Pediatric PH in Japan today  Shouzaburoh Doi(Tokyo Medical and Dental University, Japan) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:15~16:30 Biomarkers for PH diagnosis and grading  ÀÌÀç½Â(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:30~16:45 Devices for G2 PH  ÃÖÁø¿À(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:45~17:00 New trials for PH treatment  ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 17:15~17:30 Intensive PAH treatment  Hiromi Matsubara(Okayama Univ., Japan) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 17:30~17:45 Update for pulmonary hypertension management  ±èÁöÈñ(°¡Å縯ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022) : 2022-11-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Ãß°èÇмú´ëȸ : 2022-11-19
´ÙÀ½±Û ¿ï»ê±¤¿ª½ÃÀÇ»çȸ ¸¸¼ºÁúȯÀÇ ÃÖ½ÅÁö°ß : 2022-11-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
212 °æ±â ¸íÁöº´¿ø The 3nd MYONGJI INTERNATIONAL LIVER SYMPOSIUM : 2018-09-07 0 428 2018-07-28
211 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/07 : 2018-09-07 0 497 2018-07-28
210 ¼­¿ï 2018³â ¼­¿ï¾Æ»êº´¿ø ¾Ïº´¿ø ½ÉÆ÷Áö¾ö : 2018-09-07 0 540 2018-07-28
209 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ 2018³â ¹Î°£¡¤°ø°øÇù·Â(PPM) ±¹°¡°áÇÙ°ü¸®»ç¾÷ Æò°¡´ëȸ : 2018-09-07 0 613 2018-07-28
208 ´ë±¸ ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(4Â÷: °æ»óÁ¦ÁÖ±Ç) : 2018-09-07 0 624 2018-07-28
207 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-07 0 327 2018-07-28
206 ¼­¿ï °í·Á´ëÇб³¾È¾Ïº´¿ø ÀÏÂ÷ ÀÇ·áÁø°ú ÇÔ²²ÇÏ´Â ½É¹æ¼¼µ¿ÀÇ Ä¡·á : 2018-09-07 0 558 2018-07-28
205 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] ÀÇ·á»ç°í¿Í Á¶Á¤ ÁßÀç / ¼³¸íÀǹ« : 2018-09-06 0 413 2018-07-28
204 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/06 : 2018-09-06 0 379 2018-07-28
203 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-06 0 540 2018-07-28
202 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø 2018 ¾à¹°ÀÌ»ó¹ÝÀÀ ½ÉÆ÷Áö¾ö : 2018-09-05 0 964 2018-07-28
201 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-05 0 649 2018-07-28
200 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø »ç½Ã Áø·áÀÇ ÇÔÁ¤À» ÇÇÇØ°¡·Á¸é : 2018-09-04 0 1,077 2018-07-28
199 ¼­¿ï Á¦ÀϺ´¿ø 2018 »ý½Ä¹ß»ýµ¶¼º¿¬±¸ ¹× ¸¶´õ¸®½ºÅ©ÇÁ·Î±×·¥ÀÇ ÃֽŰæÇâ : 2018-09-02 0 741 2018-07-28
198 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-02 0 929 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷